Rimm DL - Search Results

1

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L. Rimm DL, et al. Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6. Breast Cancer Res. 2019. PMID: 31196152 Free PMC article.

2

Expression of c-met is a strong independent prognostic factor in breast carcinoma.

Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Ghoussoub RA, et al. Among authors: rimm eb, rimm dl. Cancer. 1998 Apr 15;82(8):1513-20. doi: 10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7. Cancer. 1998. PMID: 9554529

3

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma.

Camp RL, Rimm EB, Rimm DL. Camp RL, et al. Among authors: rimm eb, rimm dl. Cancer. 1999 Dec 1;86(11):2259-65. doi: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2. Cancer. 1999. PMID: 10590366

4

Quantitative examination of mechanophysical tumor cell enrichment in fine-needle aspiration specimens.

Ernst LM, Rimm DL. Ernst LM, et al. Among authors: rimm dl. Cancer. 2002 Oct 25;96(5):275-9. doi: 10.1002/cncr.10746. Cancer. 2002. PMID: 12378594 Free article.

5

Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Kang JY, et al. Among authors: rimm dl. Cancer Res. 2003 Mar 1;63(5):1101-5. Cancer Res. 2003. PMID: 12615728

6

Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.

Camp RL, Dolled-Filhart M, King BL, Rimm DL. Camp RL, et al. Among authors: rimm dl. Cancer Res. 2003 Apr 1;63(7):1445-8. Cancer Res. 2003. PMID: 12670887

7

Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.

Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tolgay Ocal I, et al. Among authors: rimm dl. Cancer. 2003 Apr 15;97(8):1841-8. doi: 10.1002/cncr.11335. Cancer. 2003. PMID: 12673709 Free article.

8

BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer.

Kim S, Rimm D, Carter D, Khan A, Parisot N, Franco MA, Bale A, Haffty BG. Kim S, et al. Breast J. 2003 May-Jun;9(3):167-74. doi: 10.1046/j.1524-4741.2003.09307.x. Breast J. 2003. PMID: 12752624

9

alphaB-crystallin as a marker of lymph node involvement in breast carcinoma.

Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE. Chelouche-Lev D, et al. Among authors: rimm dl. Cancer. 2004 Jun 15;100(12):2543-8. doi: 10.1002/cncr.20304. Cancer. 2004. PMID: 15197794 Free article.

10

Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.

Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. Hoek K, et al. Among authors: rimm dl. Cancer Res. 2004 Aug 1;64(15):5270-82. doi: 10.1158/0008-5472.CAN-04-0731. Cancer Res. 2004. PMID: 15289333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

514 results

Search Page

Filters